Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
T-Rex 2x Inverse Tesla Daily Target ETF
TSLZ
US Stock MarketDetailed Quotes
THAR Tharimmune
- 1.200
- -0.005-0.42%
Close Apr 25 16:00 ET
2.53MMarket Cap-0.13P/E (TTM)
1.230High1.190Low7.92KVolume1.230Open1.205Pre Close9.49KTurnover0.38%Turnover RatioLossP/E (Static)2.11MShares6.44952wk High1.94P/B2.49MFloat Cap0.95252wk Low--Dividend TTM2.08MShs Float1590.000Historical High--Div YieldTTM3.32%Amplitude0.952Historical Low1.198Avg Price1Lot Size
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Tharimmune Stock Forum
Tharimmune's preclinical data announcement marks a meaningful advancement for their multispecific antibody platform. The company's EpiClick technology appears to be delivering on its promise of accessing novel epitopes with two key candidates now showing promising in vitro potency.
The PD-1/VEGF bispecific (HS1940) represents a rational combination of immuno-oncology and anti-angiogenesis approaches. With EC50 values of 2.1nM for PD-1 and 2.56nM for VEG...
This preclinical data release demonstrates Tharimmune's progress in leveraging their EpiClick platform to produce differentiated oncology assets. Both candidates target well-validated oncology pathways but with potentially novel approaches to epitope binding.
The PD-1/VEGF bispecific space has become increasingly competitive, with Summit Therapeutics' ivonescimab leading development in the US market. Tharimmune's HS1940 attempts differentiation ...
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Monday, 7th April at 8:00 am
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with HS1940, a dual-target multispe...
FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Monday, 31st March at 8:00 am
-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway
-Company leveraging existing human pharmacokinetic data with TH104
-Advancing CMC plan to meet requirements of a New Drug Application
BRIDGEWATER, NJ / ACCESS Newswire / March 31, 2025 / Tharimmune, Inc. (...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Monday, 24th March at 8:00 am
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme...
Can Tharimmune's Dual-Target Cancer Drugs Outperform Traditional Antibody Therapies?
No comment yet